litigation Archives - Medical Design Sourcing

High-profile drugs under the legal spotlight in 2023

[Adobe Stock]

In the wake of the COVID-19 pandemic, the U.S. has witnessed a surge in litigation. One factor driving the uptick in the pharmaceutical sector is the rise of copycat litigation. As mass tort activity amplifies, plaintiff lawyers are treating previously filed lawsuits as templates for new claims. Examples of the trend include steadily increasing nitrosamines litigation and allegations of laminal duct obstruction against the chemotherapeutic agent Taxotere (docetaxel), as Greenberg Traurig has noted. Additionally, plaintiff-affiliated labs are intensifying their efforts to test various products for potentially harmful chemicals.

Amidst this backdrop, the heartburn medication Zantac (ranitidine) has found itself at the center of a litigation storm. Data from X-Ante, a litigation analysis firm, reveals the drug is the most frequent drug target of mass tort TV advertising in 2023 based on estimated ad s…

Four steps medtech startups can’t put off

Greenberg Traurig shareholder Ginger Pigott [Photo courtesy of Greenberg Traurig]

Developing and commercializing a new medical device is a success worth toasting for medtech startups — but that success also makes it more likely that litigation is in their future.

There are steps medtech startups can take to protect themselves down the road, said Greenberg Traurig shareholder Ginger Pigott, a litigator who defends major medical device manufacturers in court. She also advises medtech startups on early decisions and strategies that could have major ramifications down the road.

Pigott and two other women — Greenberg Traurig lawyer Miki Kolton and Fogarty Innovation Chief Innovation Officer Denise Zarins — will offer their expertise at our DeviceTalks West show in an Oct. 18 panel, “Going the Distance: Building Startups to Last.”

Pigott offered a preview of the panel for Medical Design &…

Novo Nordisk settles U.S. securities class action suit

Novo Nordisk (NYSE:NVO) has agreed in principle to settle securities class action litigation in the Federal District Court of New Jersey. The Bagsværd, Denmark–based company would pay $100 million in the settlement.

That amount includes plaintiffs’ attorneys’ fees, expenses and settlement costs.

The lawsuit alleged that the company made misleading statements regarding the price of its insulin.

The agreement contains no admission of liability or wrongdoing. The company stressed in a statement that it believes the “plaintiffs’ claims are without any merit.”

“While we are confident in the facts and merits of our position, we believe that resolving this matter is the right business decision for Novo Nordisk and our shareholders,” said Tomas Haagen, general counsel at Novo Nordisk.

Purchasers of American Depository Receipts initially filed the lawsuit in 2017.

Novo Nordisk, along with Eli Lilly and Sanofi-Aventis, has faced litigation ove…